Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma (MAPAC)
A Randomized Trial of Comparison of MAPI+Camrelizumbab Verus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcomaies : an Open-label, Exploratory Study
Sponsor: Chinese Sarcoma Study Group
This PHASE2 trial investigates Chemotherapy Effect and Osteosarcoma and is currently ongoing. Chinese Sarcoma Study Group leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Sarcoma Study Group
- Peking University People's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .